CCRM and the Univ of Queensland partner to commercialize neutropenia treatment

Rebecca Melville
January 24, 2017

The Univ of Toronto-hosted Centre for the Commercialization of Regenerative Medicine (CCRM) has struck a licensing deal with the UniQuest, the commercialization arm of Brisbane AU-based Univ of Queensland (UQ) to commercialize a treatment for chemotherapy-induced neutropenia. The treatment, developed by researchers at UQ’s Australian Institute for Bioengineering and Nanotechnology, provides a therapeutic dose of white blood cells from to patients immediately after chemotherapy. The white blood cells are extracted from umbilical cord blood to produce a transfusion-ready dose to administer to patients. A member of the UQ research team — Dr Nick Timmins — is now based at CCRM, which is a leader in commercializing regenerative medicine technologies and cell and gene therapies….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.